BoomRay Pharmaceuticals Signed Novartis Licensing Agreement
The biotech firm entered a global deal for a preclinical radioligand therapy.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe pharmaceutical company partnerships accelerate the availability of new medical treatments?
BoomRay Pharmaceuticals entered an exclusive global license agreement with Novartis regarding a preclinical radioligand therapy asset. The partnership aims to accelerate the development of the therapeutic program for patients worldwide.
Why it matters
This collaboration combines BoomRay discovery and development capabilities with the specialized global radioligand expertise of Novartis. The companies expect the arrangement to expedite the progression of the asset through development and regulatory milestones.
BoomRay is eligible to receive up to $900 million in payments, including upfront, development, regulatory, and sales milestones. The company is also entitled to receive royalties on future global net sales of the program.
The players
BoomRay Pharmaceuticals
Headquartered in Suzhou, China, this biotechnology company focuses on the discovery and development of innovative therapeutic assets.
Novartis
Novartis is a major multinational pharmaceutical corporation with extensive expertise in the field of radioligand therapy research.
BFC Group
BFC Group is an investment banking firm that provides financial advisory services to companies within the life sciences and healthcare sectors.
The details
The partnership leverages external innovation from the Suzhou-based biotech company alongside the internal research and development infrastructure of Novartis. BFC Group acted as the financial advisor to BoomRay throughout the negotiation process.
Timeline
September 22, 2026: BoomRay announced the global license agreement with Novartis.
The Tech Race
This agreement reflects the ongoing arms race in radioligand therapy as major pharmaceutical firms seek to secure early-stage innovation. It positions Novartis to strengthen its pipeline by integrating promising preclinical research from specialized biotech innovators.
This deal determines the speed at which this therapy moves toward clinical trials and potential market availability. The collaboration directly impacts the development timeline for new treatment options for patients worldwide.
The takeaway
Licensing agreements of this nature represent a critical pathway for small biotech firms to fund expensive clinical development through established pharmaceutical partners. Investors and patients should monitor the progress of this radioligand program as it transitions toward formal development phases.
Further reading
Learn more about the latest industry developments in the Biotech section.
More information
For more information, visit the Boomray Pharmaceuticals corporate website.
Live Poll
Do you believe pharmaceutical company partnerships accelerate the availability of new medical treatments?
